Search Results for: insulin

In the long term, capping insulin payments at $35 a month is just shuffling the deck rather than changing the game of insulin costs.

Congress should take advantage of the current political climate and start reining in the intermediaries in the drug distribution system.

Recent US media and policy attention on insulin affordability has focused on the role of manufacturers in setting prices; however, the role of other drug distribution intermediaries in determining prices has received less attention.

Schaeffer research offers one of the most comprehensive looks at the insulin distribution chain and shows which players are profiting, and by how much, from selling insulin.

Despite its discovery nearly 100 years ago, insulin’s list price has been going up, not down. New Schaeffer Center research analyzes the flow of money across all distribution system participants—manufacturers, wholesalers, pharmacies, pharmacy benefit managers (PBMs), and health plans.

Schaeffer Center researchers examined how use of insulin changes as cost-sharing fluctuates over the course of the year for Medicare Part D beneficiaries.

Schaeffer Center experts analyze the connection between medications for chronic diseases and their impact on Alzheimer’s as well as a lack of representation among racial and ethnic minorities in clinical trials.

White papers, journal articles, perspectives and more on the pharmaceutical supply chain from USC Schaeffer Center researchers.